# Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer

> **NCT05273814** · PHASE1 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Pemetrexed
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05273814
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-01
- **Primary completion:** 2023-08-01
- **Final completion:** 2024-02-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05273814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05273814, "Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05273814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*